- Conditions
- Diabetic Kidney Disease, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease, Stage 3 (Moderate)
- Interventions
- KidneyIntelX
- Diagnostic Test
- Lead sponsor
- Renalytix AI, Inc.
- Industry
- Eligibility
- 23 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetic Nephropathies
- Interventions
- PF-00489791, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 63
- States / cities
- Huntsville, Alabama • Glendale, Arizona • Tempe, Arizona + 46 more
- Conditions
- Diabetic Nephropathy
- Interventions
- SPP301
- Drug
- Lead sponsor
- Speedel Pharma Ltd.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 2,364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Diabetic Nephropathy
- Interventions
- Pyridoxamine Dihydrochloride, Placebo
- Drug
- Lead sponsor
- NephroGenex, Inc.
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetic Nephropathy, Nephrotic Syndrome
- Interventions
- ACTH
- Drug
- Lead sponsor
- Southeast Renal Research Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Chattanooga, Tennessee
- Conditions
- Chronic Kidney Disease
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 176
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more
- Conditions
- Chronic Kidney Disease, Diabetic Nephropathy
- Interventions
- Atrasentan, Placebo
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Azusa, California + 23 more
- Conditions
- Diabetic Nephropathy, Diabetic Kidney Disease
- Interventions
- Pyridorin, Placebo
- Drug
- Lead sponsor
- NephroGenex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 47 more
- Conditions
- Diabetic Nephropathies, Diabetes Mellitus, Type 2, Chronic Kidney Diseases, Healthy Lifestyle
- Interventions
- Individualized basic need navigation and lifestyle coaching and skills training, Enhanced usual care
- Behavioral
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
- Interventions
- Extended release niacin, Placebo
- Drug · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease
- Interventions
- Renal Autologous Cell Therapy (REACT)
- Biological
- Lead sponsor
- Prokidney
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Boise, Idaho • Chapel Hill, North Carolina + 1 more
- Conditions
- Type 2 Diabetes Mellitus With Diabetic Nephropathy
- Interventions
- IW-1973, Placebo
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Chula Vista, California • Fullerton, California + 42 more
- Conditions
- Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2, Chronic Kidney Diseases
- Interventions
- Patient and Community Stakeholder Interviews, Cross-sectional Study Participants, Focus Groups and Intervention Mapping
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Chronic Kidney Disease, Diabetic Nephropathy Type 2, Kidney Failure, Kidney Insufficiency
- Interventions
- Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose, Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease
- Interventions
- CTP-499, Placebo
- Drug
- Lead sponsor
- Concert Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 49
- States / cities
- Tempe, Arizona • Harrisburg, Arkansas • Little Rock, Arkansas + 38 more
- Conditions
- Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
- Interventions
- Bardoxolone methyl (amorphous dispersion)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 26
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Tempe, Arizona + 23 more
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease
- Interventions
- Renal Autologous Cell Therapy (REACT), Renal Biopsy
- Biological · Procedure
- Lead sponsor
- Prokidney
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Denver, Colorado • New Haven, Connecticut + 13 more
- Conditions
- IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
- Interventions
- Atrasentan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 14
- States / cities
- Glendale, California • Los Angeles, California • San Dimas, California + 11 more
- Conditions
- Diabetic Nephropathy
- Interventions
- Sulodexide, Placebo
- Drug
- Lead sponsor
- Keryx Biopharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,056 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetic Nephropathy
- Interventions
- LY333531
- Drug
- Lead sponsor
- Chromaderm, Inc.
- Industry
- Eligibility
- 30 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2004
- U.S. locations
- 15
- States / cities
- La Jolla, California • Walnut Creek, California • Jacksonville, Florida + 12 more
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Bariatric Surgery Candidate, Nephropathy, Diabetic Kidney Disease, Diabetes Mellitus, Type 2, Diabetes Mellitus, Diabetes Complications, Weight Loss, Diabetic Nephropathies, Adolescent Obesity, Pediatric Obesity
- Interventions
- Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL, Vertical Sleeve Gastrectomy, Renal Biopsy
- Drug · Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetic Nephropathy
- Interventions
- PF-04634817, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 65
- States / cities
- Little Rock, Arkansas • Azusa, California • Chula Vista, California + 47 more
- Conditions
- Chronic Kidney Disease, Diabetic Nephropathy
- Interventions
- Placebo for Atrasentan 0.2 mg/mL solution, 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 24
- States / cities
- Tempe, Arizona • Azusa, California • Los Angeles, California + 16 more
- Conditions
- Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
- Interventions
- Renin-Angiotensin (RAAS) alone, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
- Drug
- Lead sponsor
- James A. Tumlin, MD
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Lawrenceville, Georgia • Bethlehem, Pennsylvania